Researchers at the Perelman School of Medicine at the University of Pennsylvania have reported improvements in vision among patients with a rare inherited condition, following gene therapy.
An HIV vaccine candidate developed at the Duke Human Vaccine Institute has demonstrated the ability to trigger low levels of a rare type of neutralising antibodies (bnAbs) in a small group of participants.
£2.4 million has been funded to trials evaluating the clinical mechanisms of ADHD, with consideration to its progression with depression, parental impact, and ADHD in women.
With a particular focus on South Korea, Open Access Government explores the changing perceptions around animal welfare and some of the policies introduced to support this.
An experimental Alzheimer's drug called donanemab, developed by Eli Lilly, has demonstrated a slowdown in progression of disease at early stages, according to trial data.
Chronic liver diseases can have a detrimental impact on physical and mental health; we explore the underlying causes, symptoms, and treatment for primary biliary cholangitis.
Fusobacterium, implicated in diseases like gingivitis, ulcerative colitis, and colon cancer, has now been discovered to play a role in the formation of endometriosis.
Barney Reed, Senior Scientific Manager, Animals in Science Department at the RSPCA, stresses the need for ambitious strategies for phasing out the use of animals in science.
Barney Reed, Senior Scientific Manager, Animals in Science Department at the RSPCA, stresses the need for ambitious strategies for phasing out the use of animals in science.
The National Institute for Health and Care Research (NIHR) launches a new talking therapy for self-harm trial in an effort to reduce the number of those struggling in the UK.
The Long COVID lessons learned beyond the COVID-19 pandemic are detailed here by leading Professors working on the University College London STIMULATE-ICP programme.
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses different tuberculosis drug development regimens.
